Sequencing Quadruple Therapy for Heart Failure with Reduced Ejection Fraction: Does It Really Matter? [0.03%]
射血分数降低的心力衰竭序贯应用四种疗法：真的重要吗？
Jiun-Ruey Hu,Alexandra N Schwann,Jia Wei Tan et al.
Jiun-Ruey Hu et al.
The conventional sequence of guideline-directed medical therapy (GDMT) initiation in heart failure with reduced ejection fraction (HFrEF) assumes that the effectiveness and tolerability of GDMT agents mirror their order of discovery, which ...
The Economic Burden of Heart Failure with Reduced Ejection Fraction: Living Longer but Poorer? [0.03%]
射血分数降低的心力衰竭的经济负担：活得更长但变得更穷？
Larry A Allen,Emily Fryman Lowe,Dan D Matlock
Larry A Allen
Treatment of heart failure with reduced ejection fraction (HFrEF) has benefitted from a proliferation of new medications and devices. These treatments carry important clinical benefits, but also come with costs relevant to payers, providers...
Heart Failure with Reduced Ejection Fraction and COVID-19, when the Sick Get Sicker: Unmasking Racial and Ethnic Inequities During a Pandemic [0.03%]
射血分数降低的心衰与COVID-19：当病人病情加重时，疫情下种族和民族的不平等现象逐渐显现
Johanna Contreras,Elizabeth O Tinuoye,Alejandro Folch et al.
Johanna Contreras et al.
Minoritized racial and ethnic groups have the highest incidence, prevalence, and hospitalization rate for heart failure. Despite improvement in medical therapies and overall survival, the morbidity and mortality of these groups remain eleva...
Giuseppe Limongelli,Emanuele Monda,Eduardo Bossone et al.
Giuseppe Limongelli et al.
Specific Therapy in Transthyretin Amyloid Cardiomyopathy: Future Perspectives Beyond Tafamidis [0.03%]
转甲状腺素蛋白淀粉样变性心肌病的特异性治疗：塔法木司之外的未来展望
Riccardo Saro,Valentina Allegro,Marco Merlo et al.
Riccardo Saro et al.
Transthyretin amyloid cardiomyopathy (ATTR-CM) is a relatively prevalent cause of morbidity and mortality. Over the recent years, development of disease-modifying treatments has enabled stabilization of the circulating transthyretin tetrame...
Tafamidis in the Treatment of ATTR-related Cardiomyopathy: Indications and Grey Zones [0.03%]
心肌淀粉样变性相关心脏病tafamidis治疗的适应症与争议领域
Teresa Maria Capovilla,Andrea Lalario,Maddalena Rossi et al.
Teresa Maria Capovilla et al.
Transthyretin amyloid cardiomyopathy (ATTR-CM) is caused by the myocardial extracellular deposition of amyloid fibrils formed from the dissociation of TTR tetramer into monomers. The rate-limiting step in TTR amyloidogenesis is the dissocia...
Standard Therapy in Cardiac Amyloidosis: What is Known, What is "Gray" [0.03%]
心脏淀粉样变性的一线治疗：已知事项和“灰区”
Annamaria Del Franco,Giulia Biagioni,Carlotta Mazzoni et al.
Annamaria Del Franco et al.
Amyloidosis is a systemic disease due to the accumulation of misfolded amyloid fibrils that damage the heart and worsen the prognosis. Heart failure (HF), a condition frequently linked with an advanced stage of this disease, is the most pre...
Genotype-Phenotype Correlations in ATTR Amyloidosis: A Clinical Update [0.03%]
ATTR淀粉样变的基因型与表型的相关性：临床最新研究进展
Emanuele Monda,Chiara Cirillo,Federica Verrillo et al.
Emanuele Monda et al.
Hereditary transthyretin-related amyloidosis (hATTR) is the most common form of familial amyloidosis. It is an autosomal dominant disease caused by a pathogenic variant in the TTR gene. More than 140 TTR gene variants have been associated w...
The Role of Scintigraphy with Bone Radiotracers in Cardiac Amyloidosis [0.03%]
放射性骨示踪剂心肌灌注显像在心脏淀粉样变中的作用
Paolo Morfino,Alberto Aimo,Assuero Giorgetti et al.
Paolo Morfino et al.
Cardiac amyloidosis (CA) is caused by the myocardial deposition of misfolded proteins, either amyloid transthyretin (ATTR) or immunoglobulin light chains (AL). The paradigm of this condition has transformed, since CA is increasingly recogni...
Cardiovascular Magnetic Resonance in the Management of Cardiac Amyloidosis: Current and Future Clinical Applications [0.03%]
心脏淀粉样变管理中的心血管磁共振：当前和未来的临床应用
Andrea Barison,Ignazio Alessio Gueli,Fausto Pizzino et al.
Andrea Barison et al.
Cardiac magnetic resonance represents the gold standard imaging technique to assess cardiac volumes, wall thickness, mass, and systolic function but also to provide noninvasive myocardial tissue characterization across almost all cardiac di...